enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
4.540
-0.040 (-0.87%)
Aug 14, 2025, 11:48 AM - Market open
enVVeno Medical Employees
enVVeno Medical had 37 employees as of December 31, 2024. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$623,459
Market Cap
87.38M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37 | 6 | 19.35% |
Dec 31, 2023 | 31 | 1 | 3.33% |
Dec 31, 2022 | 30 | 6 | 25.00% |
Dec 31, 2021 | 24 | 5 | 26.32% |
Dec 31, 2020 | 19 | 7 | 58.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NVNO News
- 8 days ago - Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency - Accesswire
- 10 days ago - enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company - Accesswire
- 13 days ago - enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 23 days ago - enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - Accesswire
- 2 months ago - Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Accesswire
- 3 months ago - enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Accesswire
- 3 months ago - Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - Accesswire
- 3 months ago - enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Accesswire